Why Zhengye Biotechnology Holding Limited’s (ZYBT) Stock Is Up 5.27%

By Jenna Brashear
May 08, 2026
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Zhengye Biotechnology Holding Limited before investing.

In this article, we go over a few key elements for understanding Zhengye Biotechnology Holding Limited’s stock price such as:

  • Zhengye Biotechnology Holding Limited’s current stock price and volume
  • Why Zhengye Biotechnology Holding Limited’s stock price changed recently
  • Upgrades and downgrades for ZYBT from analysts
  • ZYBT’s stock price momentum as measured by its relative strength

About Zhengye Biotechnology Holding Limited (ZYBT)

Before we jump into Zhengye Biotechnology Holding Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals. In addition, it exports its products to Vietnam, Pakistan, and Egypt. The company serves direct-end customers, including livestock farmers and local governments, as well as domestic distributors and exporting distributors. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Want to learn more about Zhengye Biotechnology Holding Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Zhengye Biotechnology Holding Limited.

Learn More About A+ Investor

Zhengye Biotechnology Holding Limited’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, Zhengye Biotechnology Holding Limited’s stock price was $0.950.

Zhengye Biotechnology Holding Limited is down 2.87% from its previous closing price of $0.978.

During the last market session, Zhengye Biotechnology Holding Limited’s stock traded between $0.950 and $0.980. Currently, there are approximately 0.00 million shares outstanding for Zhengye Biotechnology Holding Limited.

Zhengye Biotechnology Holding Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Zhengye Biotechnology Holding Limited Stock Price History

Zhengye Biotechnology Holding Limited’s (ZYBT) price is currently up 3.21% so far this month.

During the month of May, Zhengye Biotechnology Holding Limited’s stock price has reached a high of $1.300 and a low of $0.800.

Over the last year, Zhengye Biotechnology Holding Limited has hit prices as high as $13.790 and as low as $0.680. Year to date, Zhengye Biotechnology Holding Limited’s stock is down 17.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Zhengye Biotechnology Holding Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were analysts who downgraded Zhengye Biotechnology Holding Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Zhengye Biotechnology Holding Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Zhengye Biotechnology Holding Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Zhengye Biotechnology Holding Limited (ZYBT) by visiting AAII Stock Evaluator.

Relative Price Strength of Zhengye Biotechnology Holding Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Zhengye Biotechnology Holding Limited has a weighted four-quarter relative price strength of -32.60%, which translates to a Momentum Score of 4 and is considered to be Very Weak.

Want to learn more about how Zhengye Biotechnology Holding Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Zhengye Biotechnology Holding Limited Stock Price: Bottom Line

As of May 8, 2026, Zhengye Biotechnology Holding Limited’s stock price is $0.950, which is down 2.87% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Zhengye Biotechnology Holding Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
O'Neil CAN SLIM Screen: 38.3% Compared to S&P 500
at only 23.3%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.